120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
脂质体布比卡因用于剖宫产术后局部浸润镇痛的ED95：一项随机对照试验
Authors Liu J, Zhang Y, Liu L, Zhang W
Received 2 October 2025
Accepted for publication 25 January 2026
Published 6 February 2026 Volume 2026:20 571871
DOI https://doi.org/10.2147/DDDT.S571871
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 1
Editor who approved publication: Dr Muzammal Hussain
Jiafei Liu,1,* Yang Zhang,1,* Lin Liu,2 Wangping Zhang3
1Department of Anesthesiology, Ninghai First Hospital, Ninghai, Zhejiang, 315600, People’s Republic of China; 2Department of Anesthesiology, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang, 314000, People’s Republic of China; 3Department of Anesthesiology, Women and Children’s Hospital of Jiaxing University, Jiaxing, Zhejiang, 314000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Lin Liu, Email 13967358623@163.com Wangping Zhang, Email zhan650679@163.com
Background: At present, the median effective dose (ED50) and effective dose for 95% of patients (ED95) of liposomal bupivacaine for local infiltration analgesia following cesarean section have not been established. This study aimed to determine the ED95 of liposomal bupivacaine for local infiltration analgesia in patients following cesarean section.
Methods: A total of 72 primiparas scheduled to undergo lower segment cesarean sections, were randomly divided into four groups: Group 1, Group 2, Group 3, and Group 4, with 18 cases in each group. When suturing to the fascial layer, the four groups received 66.5 mg, 133 mg, 199.5 mg, and 266 mg of liposomal bupivacaine for incision infiltration analgesia, respectively. The pain intensity at coughing was assessed using a visual analog scale (VAS) within 48 hours postoperatively. Effective analgesia was defined as a VAS score of ≤ 3. The ED95 and the 95% confidence interval (CI) of liposomal bupivacaine for local infiltration analgesia after cesarean section were calculated using probit regression analysis.
Results: The ED50 and ED95 of liposomal bupivacaine for local infiltration analgesia following cesarean section were 128.5mg (95% CI, 106.8 to 194.4mg) and 206.1 (95% CI, 178.6 to 262.5mg), respectively.
Conclusion: This study indicated that the ED95 of liposomal bupivacaine for local infiltration analgesia following cesarean section was 206.1 mg (95% CI, 178.6, 262.5 mg). (registration number: ChiCTR2300076315).
Keywords: liposomal bupivacaine, cesarean section, incision infiltration, postoperative analgesia, ED95
1Department of Anesthesiology, Ninghai First Hospital, Ninghai, Zhejiang, 315600, People’s Republic of China; 2Department of Anesthesiology, Zhejiang Rongjun Hospital, Jiaxing, Zhejiang, 314000, People’s Republic of China; 3Department of Anesthesiology, Women and Children’s Hospital of Jiaxing University, Jiaxing, Zhejiang, 314000, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Lin Liu, Email 13967358623@163.com Wangping Zhang, Email zhan650679@163.com
Background: At present, the median effective dose (ED50) and effective dose for 95% of patients (ED95) of liposomal bupivacaine for local infiltration analgesia following cesarean section have not been established. This study aimed to determine the ED95 of liposomal bupivacaine for local infiltration analgesia in patients following cesarean section.
Methods: A total of 72 primiparas scheduled to undergo lower segment cesarean sections, were randomly divided into four groups: Group 1, Group 2, Group 3, and Group 4, with 18 cases in each group. When suturing to the fascial layer, the four groups received 66.5 mg, 133 mg, 199.5 mg, and 266 mg of liposomal bupivacaine for incision infiltration analgesia, respectively. The pain intensity at coughing was assessed using a visual analog scale (VAS) within 48 hours postoperatively. Effective analgesia was defined as a VAS score of ≤ 3. The ED95 and the 95% confidence interval (CI) of liposomal bupivacaine for local infiltration analgesia after cesarean section were calculated using probit regression analysis.
Results: The ED50 and ED95 of liposomal bupivacaine for local infiltration analgesia following cesarean section were 128.5mg (95% CI, 106.8 to 194.4mg) and 206.1 (95% CI, 178.6 to 262.5mg), respectively.
Conclusion: This study indicated that the ED95 of liposomal bupivacaine for local infiltration analgesia following cesarean section was 206.1 mg (95% CI, 178.6, 262.5 mg). (registration number: ChiCTR2300076315).
Keywords: liposomal bupivacaine, cesarean section, incision infiltration, postoperative analgesia, ED95